Peter F Ambros

List of Publications by Year in Descending Order

187 papers	13,574 citations	54 h-index	114 g-index
203 ext. papers	15,627 ext. citations	7.1 avg, IF	5.57 L-index

#	Paper	IF	Citations
187	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. *Nature Communications*, **2021**, 12, 6804	17.4	8
186	Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9	2
185	Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8. *Nature Communications*, **2021**, 12, 1624	17.4	16
184	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. *Nature Communications*, **2021**, 12, 3230	17.4	17
183	Frequency and Prognostic Impact of Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). *Journal of Clinical Oncology*, **2021**, 39, 3377-3390	2.2	5
182	Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation. *IEEE Transactions on Medical Imaging*, **2021**, 40, 1934-1949	11.7	10
181	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. *Nature Communications*, **2021**, 12, 1269	17.4	12
180	Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging. *Cancers*, **2021**, 13,	6.6	1
179	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. *Journal of Clinical Oncology*, **2021**, 39, 2552-2563	2.2	9
178	Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. *Journal of Molecular Diagnostics*, **2020**, 22, 1070-1086	5.1	26
177	Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. *Journal of Clinical Oncology*, **2020**, 38, 2902-2915	2.2	23
176	Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). *Cancers*, **2020**, 12,	6.6	35
175	An annotated fluorescence image dataset for training nuclear segmentation methods. *Scientific Data*, **2020**, 7, 262	8.2	15
174	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. *Journal of Clinical Oncology*, **2020**, 38, 3685-3697	2.2	2
173	Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front□ne high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.. *Journal of Clinical Oncology*,	2.2	7
172	DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data. *Journal of Computational Biology*, **2019**, 26, 572-596	1.7	2
171	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. *Journal of the National Cancer Institute*, **2018**, 110, 1084-1093	9.7	43

170	Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells. *Methods in Molecular Biology*, **2018**, 1739, 67-86	1.4	12
169	Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. *International Journal of Cancer*, **2018**, 142, 297-307	7.5	10
168	Immunotherapy with anti-GD2 antibody ch14.18/CHO□IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.. *Journal of Clinical Oncology*, **2018**, 36, 10539-10539	2.2	5
167	Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?. *Journal of Clinical Oncology*, **2018**, 36, 10550-10550	2.2	
166	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1617-1629	21.7	138
165	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. *British Journal of Cancer*, **2018**, 118, 1502-1512	8.7	15
164	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. *Nature Medicine*, **2017**, 23, 386-395	50.5	128
163	Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. *Clinical Cancer Research*, **2017**, 23, 4224-4232	12.9	19
162	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 500-514	21.7	188
161	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. *Cancer*, **2017**, 123, 1095-1105	6.4	48
160	Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. *Oncogene*, **2016**, 35, 1423-32	9.2	20
159	Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype. *Glia*, **2016**, 64, 2133-2153	9	44
158	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. *Journal of Clinical Oncology*, **2016**, 34, 3195-203	2.2	75
157	Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. *Cancer*, **2016**, 122, 935-45	6.4	44
156	Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. *Oncotarget*, **2016**, 7, 3571-86	3.3	29
155	Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors. *PLoS ONE*, **2016**, 11, e0161369	3.7	4
154	Machine learning framework incorporating expert knowledge in tissue image annotation **2016**,		4
153	Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. *Acta Neuropathologica Communications*, **2016**, 4, 88	7.3	31

152	The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. *International Journal of Cancer*, **2016**, 139, 153-63	7.5	24
151	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. *British Journal of Cancer*, **2015**, 112, 290-5	8.7	27
150	Semi-automated segmentation of neuroblastoma nuclei using the gradient energy tensor: a user driven approach **2015**,		1
149	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *Journal of Clinical Oncology*, **2015**, 33, 3008-17	2.2	433
148	Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. *Molecular Oncology*, **2015**, 9, 545-54	7.9	15
147	Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies-A Validation Study. *PLoS ONE*, **2015**, 10, e0137995	3.7	5
146	Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. *Oncotarget*, **2015**, 6, 35247-62	3.3	38
145	Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. *Pediatric Blood and Cancer*, **2014**, 61, 627-35	3	54
144	Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma. *European Journal of Cancer*, **2014**, 50, 622-7	7.5	4
143	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. *Journal of Clinical Oncology*, **2014**, 32, 1228-35	2.2	22
142	Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. *Journal of Clinical Oncology*, **2014**, 32, 3169-76	2.2	106
141	Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Pediatric Blood and Cancer*, **2014**, 61, 1932-9	3	25
140	Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. *Frontiers in Oncology*, **2014**, 4, 202	5.3	34
139	Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.. *Journal of Clinical Oncology*, **2014**, 32, 10026-10026	2.2	3
138	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. *Journal of Clinical Oncology*, **2013**, 31, 10015-10015	2.2	
137	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. *European Journal of Cancer*, **2012**, 48, 1185-91	7.5	11
136	Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. *British Journal of Cancer*, **2012**, 107, 1418-22	8.7	117
135	Redirecting T cells to Ewing© sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. *PLoS ONE*, **2012**, 7, e31210	3.7	87

134	Chromosomally integrated human herpesvirus 6: questions and answers. *Reviews in Medical Virology*, **2012**, 22, 144-55	11.7	261
133	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. *European Journal of Cancer*, **2011**, 47, 561-71	7.5	81
132	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). *British Journal of Cancer*, **2011**, 105, 1940-8	8.7	65
131	Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Journal of Clinical Oncology*, **2011**, 29, 3286-92	2.2	187
130	Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. *Journal of Clinical Oncology*, **2011**, 29, 4358-64	2.2	45
129	Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. *Journal of Clinical Oncology*, **2011**, 29, 449-55	2.2	78
128	A multilocus technique for risk evaluation of patients with neuroblastoma. *Clinical Cancer Research*, **2011**, 17, 792-804	12.9	37
127	DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. *PLoS Genetics*, **2011**, 7, e1002042	6	47
126	The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5563-8	11.5	255
125	Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. *Genome Research*, **2010**, 20, 1198-206	9.7	132
124	Sequence-based high resolution chromosomal comparative genomic hybridization (CGH). *Methods in Molecular Biology*, **2010**, 659, 299-312	1.4	
123	Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. *International Journal of Cancer*, **2010**, 126, 2025-35	7.5	41
122	Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. *Journal of Clinical Oncology*, **2009**, 27, 365-70	2.2	92
121	The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. *Journal of Clinical Oncology*, **2009**, 27, 298-303	2.2	613
120	Free DNA in the blood serum can unmask MYCN amplified tumors. *Pediatric Blood and Cancer*, **2009**, 53, 306-7	3	1
119	In vitro and in vivo profiling of P-glycoprotein in human neuroblastoma and rhabdomyosarcoma cells under simvastatin exposure. *BMC Pharmacology*, **2009**, 9, A16		78
118	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. *British Journal of Cancer*, **2009**, 100, 1471-82	8.7	255
117	The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *Journal of Clinical Oncology*, **2009**, 27, 289-97	2.2	1134

116	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. *Lancet Oncology, The*, **2009**, 10, 663-71	21.7	145
115	Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. *British Journal of Cancer*, **2008**, 99, 1027-33	8.7	93
114	Identification of the human homolog of the imprinted mouse Air non-coding RNA. *Genomics*, **2008**, 92, 464-73	4.3	42
113	Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. *American Journal of Pathology*, **2008**, 172, 203-14	5.8	21
112	Sequence based high resolution chromosomal CGH. *Cytogenetic and Genome Research*, **2008**, 121, 1-6	1.9	4
111	hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F1365-75	4.3	200
110	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. *International Journal of Cancer*, **2008**, 122, 1177-82	7.5	17
109	Modulation of multidrug resistance proteins by statins in human neuroblastoma. *BMC Pharmacology*, **2008**, 8, A24		78
108	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. *Pediatric Blood and Cancer*, **2008**, 51, 589-92	3	45
107	Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. *Genes Chromosomes and Cancer*, **2007**, 46, 130-42	5	27
106	Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. *Genes Chromosomes and Cancer*, **2007**, 46, 163-70	5	47
105	Clinical appearance of neuroblastoma 10 years after screening. *Pediatric Blood and Cancer*, **2007**, 49, 1012-4	3	
104	Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. *Pediatric Blood and Cancer*, **2007**, 48, 504-9	3	95
103	FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. *Cell Death and Differentiation*, **2007**, 14, 534-47	12.7	142
102	A new platform linking chromosomal and sequence information. *Chromosome Research*, **2007**, 15, 327-39	4.4	5
101	SKY analysis of childhood neural tumors and cell lines demonstrates a susceptibility of aberrant chromosomes to further rearrangements. *Cancer Letters*, **2007**, 250, 47-52	9.9	2
100	Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization. *International Journal of Cancer*, **2006**, 118, 1603-8	7.5	20
99	Neuroblastome **2006**, 829-846		1

98	Treatment complications in neuroblastoma patients: lessons from screening studies. *Journal of Clinical Oncology*, **2006**, 24, e41	2.2	1
97	Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. *American Journal of Surgical Pathology*, **2006**, 30, 1462-8	6.7	136
96	Detecting minimal residual disease in neuroblastoma patients-the present state of the art. *Cancer Letters*, **2005**, 228, 229-40	9.9	42
95	Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. *Journal of Histochemistry and Cytochemistry*, **2005**, 53, 1433-40	3.4	39
94	Automatic telomere length measurements in interphase nuclei by IQ-FISH. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2005**, 68, 113-20	4.6	39
93	Treatment of Neuroblastoma. *Pediatric Oncology*, **2005**, 123-192	0.5	2
92	Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. *Journal of Clinical Oncology*, **2005**, 23, 2280-99	2.2	145
91	DEC1 expression in 1p-aberrant oligodendroglial neoplasms. *Histology and Histopathology*, **2005**, 20, 1173-7	1.4	11
90	Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. *Oncology Reports*, **2005**, 13, 179-84	3.5	27
89	Combined immunofluorescence and FISH: new prospects for tumor cell detection/identification. *Current Protocols in Cytometry*, **2004**, Chapter 8, Unit 8.13	3.6	
88	Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. *Clinical Cancer Research*, **2004**, 10, 6567-71	12.9	12
87	Rapid determination of Epstein-Barr virus latent or lytic infection in single human cells using in situ hybridization. *Modern Pathology*, **2004**, 17, 1564-72	9.8	17
86	Automatic quantification of gene amplification in clinical samples by IQ-FISH **2004**, 57, 15-22		11
85	Molecular analysis of the putative tumour-suppressor gene EXTL1 in neuroblastoma patients and cell lines. *European Journal of Cancer*, **2004**, 40, 1255-61	7.5	9
84	Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. *Brain Pathology*, **2003**, 13, 133-43	6	108
83	Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. *Journal of Clinical Oncology*, **2003**, 21, 4228-34	2.2	26
82	Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. *Modern Pathology*, **2003**, 16, 708-15	9.8	46
81	Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. *American Journal of Pathology*, **2003**, 163, 393-9	5.8	33

80	Disseminated tumor cells in the bone marrow - chances and consequences of microscopical detection methods. *Cancer Letters*, **2003**, 197, 29-34	9.9	14
79	Quality assessment of genetic markers used for therapy stratification. *Journal of Clinical Oncology*, **2003**, 21, 2077-84	2.2	109
78	Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. *Cancer Genetics and Cytogenetics*, **2002**, 135, 128-38		16
77	Neuroblastoma with focal MYCN amplification and bone marrow infiltration: a staging and treatment dilemma. *Medical and Pediatric Oncology*, **2002**, 38, 109-11		17
76	Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma. *Genes Chromosomes and Cancer*, **2002**, 33, 285-94	5	29
75	Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt lymphoma, and Hodgkin lymphoma. *Annals of Hematology*, **2002**, 81, 441-7	3	12
74	Prognostic impact of chromosomal aberrations in Ewing tumours. *British Journal of Cancer*, **2002**, 86, 1763-9	8.7	77
73	Neuroblastoma screening in early life. *New England Journal of Medicine*, **2002**, 347, 852-4; author reply 852-4	59.2	1
72	Frequent low level expression in Ewing sarcoma family tumors and widespread absence of the metastasis suppressor KAI1/CD82 in neuroblastoma. *Pediatric Research*, **2002**, 52, 279-85	3.2	3
71	Detection and relocation of rare events. A comparative study using the laser scanning cytometer and the Metafer/RCDetect microscope scanning system. *Journal of Proteomics*, **2002**, 53, 109-15		5
70	Characterisation of pericentrometric and sticky intercalary heterochromatin in Ornithogalum longibracteatum (Hyacinthaceae). *Chromosoma*, **2001**, 110, 203-13	2.8	33
69	Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. *Medical and Pediatric Oncology*, **2001**, 37, 492-504		121
68	Neuroblastoma cells provoke Schwann cell proliferation in vitro. *Medical and Pediatric Oncology*, **2001**, 36, 163-8		25
67	Automatic detection and genetic profiling of disseminated neuroblastoma cells. *Medical and Pediatric Oncology*, **2001**, 36, 205-9		14
66	Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. *Medical and Pediatric Oncology*, **2001**, 36, 61-6		30
65	Prognostic significance of DNA di-tetraploidy in neuroblastoma. *Medical and Pediatric Oncology*, **2001**, 36, 83-92		49
64	Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. *Oncogene*, **2001**, 20, 4402-8	9.2	100
63	Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. *Journal of Biological Chemistry*, **2001**, 276, 13192-7	5.4	29

62	Circulating breast cancer cells are frequently apoptotic. *American Journal of Pathology*, **2001**, 159, 17-20	5.8	210
61	Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines*□**2001**, 37, 492		4
60	Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. *Medical and Pediatric Oncology*, **2000**, 35, 688-91		39
59	Classification of isolated tumor cells and micrometastasis. *Cancer*, **2000**, 89, 709-11	6.4	7
58	Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis. *Cytometry*, **2000**, 42, 357-62		25
57	Molecular analysis of chromosome arm 17q gain in neuroblastoma. *Genes Chromosomes and Cancer*, **2000**, 28, 276-84	5	23
56	Chromosomal regions involved in the pathogenesis of osteosarcomas. *Genes Chromosomes and Cancer*, **2000**, 28, 329-36	5	96
55	Peripheral primitive neuroectodermal tumour of the cervix. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 436, 68-73	5.1	35
54	In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing sarcomas and peripheral primitive neuroectodermal tumors. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 437, 234-40	5.1	9
53	Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. *Oncogene*, **1999**, 18, 233-8	8.2	64
52	Intraspinal primitive neuroectodermal tumour: report of two cases and review of the literature. *Acta Neurochirurgica*, **1999**, 141, 1169-75	3	44
51	Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. *Genes Chromosomes and Cancer*, **1999**, 24, 243-54	5	67
50	Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature*, **1998**, 394, 203-6	50.4	1200
49	Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. *International Journal of Cancer*, **1998**, 79, 56-60	7.5	82
48	Neuroblastoma screening for children: delay, repeat, or delete?. *Medical and Pediatric Oncology*, **1998**, 31, 111-2		
47	Biological aspects of neuroblastoma screening. *Medical and Pediatric Oncology*, **1998**, 31, 394-400		12
46	Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **1998**, 23, 141-52	5	106
45	Localization of the human I-kappaB kinase-beta (IKBKB) to chromosome 8p11.2 by fluorescence in situ hybridization and radiation hybrid mapping. *Genomics*, **1998**, 54, 575-6	4.3	1

44	Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. *Genome Research*, **1998**, 8, 929-39	9.7	50
43	The Ig Heavy Chain 3? End Confers a Posttranscriptional Processing Advantage to Bcl-2/IgH Fusion RNA in t(14;18) Lymphoma. *Blood*, **1998**, 91, 3952-3961	2.2	1
42	Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. *Oncogene*, **1997**, 15, 2225-32	9.2	126
41	Neuroblastoma screening in infants postponed after the sixth month of age: a trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features. *Medical and Pediatric Oncology*, **1997**, 29, 1-10		32
40	Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. *New England Journal of Medicine*, **1996**, 334, 1505-11	59.2	205
39	Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. *Journal of Clinical Oncology*, **1996**, 14, 373-81	2.2	93
38	International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. *Journal of Clinical Oncology*, **1996**, 14, 2174-80	2.2	45
37	Isochromosome 12p and maternal loss of 1p36 in a pediatric testicular germ cell tumor. *Cancer Genetics and Cytogenetics*, **1996**, 91, 95-100		13
36	Metastatic extraosseous Ewing tumor. Association of the additional translocation der(16)t(1;16) with the variant EWS/ERG rearrangement in a case of cytogenetically inconspicuous chromosome 22. *Cancer Genetics and Cytogenetics*, **1996**, 87, 161-6		10
35	Connatal localized neuroblastoma. The case to delay treatment. *Cancer*, **1996**, 77, 1395-401	6.4	33
34	Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of Ewing tumors. *Genes Chromosomes and Cancer*, **1996**, 17, 141-50	5	31
33	Demethylation of repetitive DNA sequences in neuroblastoma. *Genes Chromosomes and Cancer*, **1996**, 17, 234-44	5	37
32	Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism. *DNA and Cell Biology*, **1996**, 15, 41-51	3.6	16
31	Connatal localized neuroblastoma: The case to delay treatment **1996**, 77, 1395		1
30	Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. *International Journal of Cancer*, **1995**, 64, 135-9	7.5	72
29	The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. *New England Journal of Medicine*, **1994**, 331, 294-9	59.2	894
28	Homology-dependent gene silencing in transgenic plants: epistatic silencing loci contain multiple copies of methylated transgenes. *Molecular Genetics and Genomics*, **1994**, 244, 219-29		163
27	Interphase cytogenetic study of childhood acute lymphoblastic leukemia. *Medical and Pediatric Oncology*, **1994**, 23, 413-21		14

26	Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. *Genes Chromosomes and Cancer*, **1994**, 11, 40-50	5	65
25	Double-target FISH in the diagnosis of Ewing tumors. *Cancer Genetics and Cytogenetics*, **1994**, 77, 202		2
24	Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. *British Journal of Cancer*, **1994**, 70, 908-13	8.7	86
23	Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. *Cytogenetic and Genome Research*, **1993**, 63, 24-8	1.9	52
22	Translocation (12;13) in a case of infantile fibrosarcoma. *Cancer Genetics and Cytogenetics*, **1993**, 71, 94-6		14
21	Detection of Ip36 deletions in paraffin sections of neuroblastoma tissues. *Genes Chromosomes and Cancer*, **1993**, 6, 1-9	5	43
20	Non-random integration of Epstein-Barr virus in lymphoblastoid cell lines. *Genes Chromosomes and Cancer*, **1993**, 8, 38-48	5	27
19	Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life. *Medical and Pediatric Oncology*, **1993**, 21, 625-6		9
18	Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13 [corrected]. *Genomics*, **1992**, 13, 219-24	4.3	68
17	MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. *Cancer*, **1991**, 67, 1886-93	6.4	568
16	Autologous rescue with blood-derived stem cells in a child with non-Hodgkin's lymphoma. *Pediatric Hematology and Oncology*, **1990**, 7, 137-44	1.7	4
15	Cytomegalovirus (CMV) disease of the brain in AIDS and connatal infection: a comparative study by histology, immunocytochemistry and in situ DNA hybridization. *Acta Neuropathologica*, **1989**, 79, 286-93	14.3	51
14	Herpes simplex virus (HSV) DNA in microglial nodular brainstem encephalitis. *Journal of Neuropathology and Experimental Neurology*, **1989**, 48, 645-52	3.1	27
13	Comparison of in situ DNA hybridization (ISH) and immunocytochemistry for diagnosis of herpes simplex virus (HSV) encephalitis in tissue. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1988**, 414, 39-43		13
12	Translocation t(8;16) in acute monocytic leukemia. *Cancer Genetics and Cytogenetics*, **1988**, 34, 265-71		27
11	Correlation of pachytene chromomeres and metaphase bands of human chromosomes, and distinctive properties of telomeric regions. *Cytogenetic and Genome Research*, **1987**, 44, 223-8	1.9	48
10	Immunoenzymatic staining methods for simultaneous demonstration of chromosomes and cell surface markers. *Cancer Genetics and Cytogenetics*, **1987**, 27, 229-40		12
9	Trisomy 14 in refractory anemia with excess of blasts in transformation. *Cancer Genetics and Cytogenetics*, **1987**, 29, 315-8		12

8	Chromosomal insertion of human papillomavirus 18 sequences in HeLa cells detected by nonisotopic in situ hybridization and reflection contrast microscopy. *Human Genetics*, **1987**, 77, 251-4	6.3	35
7	Short arm dicentric Y chromosome with associated statural defects in a sterile man. *Human Genetics* , **1986**, 73, 350-3	6.3	47
6	Detection of a 17 kb unique sequence (T-DNA) in plant chromosomes by in situ hybridization. *Chromosoma*, **1986**, 94, 11-18	2.8	147
5	Application of Giemsa banding to orchid karyotype analysis. *Plant Systematics and Evolution*, **1980**, 134, 293-297	1.3	186
4	Analysis of nucleolus organizer regions (NORs) in mitotic and polytene chromosomes ofPhaseolus coccineus by silver staining and Giemsa C-banding. *Plant Systematics and Evolution*, **1979**, 132, 27-51	1.3	28
3	A case of trisomy 22 in Pongo pygmaeus. *Cytogenetic and Genome Research*, **1979**, 24, 1-6	1.9	29
2	Modification of DAPI banding on human chromosomes by prestaining with a DNA-binding oligopeptide antibiotic, distamycin A. *Experimental Cell Research*, **1978**, 111, 327-32	4.2	260
1	Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8		1